

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-16 (canceled).

C
Claim 17 (currently amended): A method for vaccinating a human against a human immunodeficiency virus comprising the ~~[[steps]]~~step of:

~~selecting an immunogen competent to induce a protective immune response in said human against said human immunodeficiency virus, and~~

administering to said human an effective amount of ~~[[said]]~~ an immunogen comprising an attenuated form of said human immunodeficiency virus ~~to said human~~ sufficient to induce a cell mediated response against said human immunodeficiency virus but below the amount necessary to induce ~~[[a]]~~ an offsetting humoral response to said human immunodeficiency virus.

Claims 20-31 (canceled).

Claim 32 (currently amended): The method of claim ~~[[31]]~~ 17, wherein said ~~immunogen~~ human immunodeficiency virus has been inactivated by removing a sufficient portion of its genetic material so as to render it incapable of replicating.

Claim 33 (currently amended): The method of claim 32, wherein the genetic material removed from said human immunodeficiency virus is a portion of a gene coding for a gag ~~[[gag]]~~ nucleocapsid protein.

Claims 34-39 (canceled).

Appl. No. 09/769,223
Amdt. dated August 5, 2003
Reply to Office Action of March 6, 2003

PATENT

CI
cont'd
Claim 40 (new): The method of claim 17, wherein the human
immunodeficiency virus is HIV-1.

Claim 41 (new): The method of claim 17, wherein the human
immunodeficiency virus is HIV-2.

Claim 42 (new): The method of claim 33, wherein the human
immunodeficiency virus is HIV-1.

Claim 43 (new): The method of claim 33, wherein the human
immunodeficiency virus is HIV-2.

Claim 44 (new): The method of claim 17, wherein the immunogen is
administered to the mucosa.
